Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDA
- 1 March 2016
- journal article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 37 (3) , 184-191
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Drug Shortages: A Complex Health Care CrisisMayo Clinic Proceedings, 2014
- Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety chargesBMJ, 2013
- Withdrawal of Generic Budeprion for NonbioequivalenceNew England Journal of Medicine, 2012
- Lower phenytoin serum levels in persons switched from brand to generic phenytoinNeurology, 2004
- Longer Patents for Increased Generic Competition in the USPharmacoEconomics, 1996